共 50 条
- [41] Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upBLOOD, 2023, 142Song, YuqinZhou, KeshuLi, DengjuHu, JiandaZou, DehuiGao, SujunYang, HaiyanZhang, HuilaiJi, JieXu, WeiFeng, RuJin, JieLyu, FangfangFang, ChengXu, ShengZhu, Jun
- [42] Long-term safety profile of adalimumab versus ustekinumab in psoriasis: A real world matching-adjusted indirect comparison (MAIC)JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB235 - AB235Wu, Jashin J.Singh, RakeshYang, MinLi, JunlongBereswill, MareikeGarcia-Horton, VivianaValdecantos, WendellArikan, DilekWeiss, Stefan
- [43] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic LeukemiaBLOOD, 2021, 138Davids, Matthew S.Emeribe, UgochinyereGaitonde, PriyankaCai, Ling
- [44] Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)BLOOD, 2023, 142Thieblemont, CatherineConconi, AnnaritaBuske, ChristianLuminari, StefanoDreyling, Martinda Silva, Maria GomesAndre, MarcFlores, MariaBrahami-Aissou, KarimaCony-Makhoul, PascaleCarras, Sylvain
- [45] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Moreau, PhilippeUsmani, Saad Zafarvan de Donk, Niels W. C. J.Garfall, Alfred L.Delforge, MichelRocafiguera, Albert OriolNooka, Ajay K.Rosinol, LauraBahlis, Nizar J.Rodriguez-Otero, PaulaMartin, Thomas G.Diels, JorisVan Sanden, SuzyPei, LixiaAmmann, EricKobos, RachelSlavcev, MarySmit, JenniferLondhe, AnilKrishnan, Amrita Y.
- [46] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Sehn, Laurie HelenScholz, Christian W.Luminari, StefanoSalar, AntonioWahlin, Bjorn E.Gopal, Ajay K.Bonnet, Christophe MarcPaneesha, ShankaraManzke, OliverSeguy, FrancisLi, DiHuebel, Kai
- [47] Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphomaExperimental Hematology & Oncology, 14 (1)Loretta J. NastoupilAshley BonnerPearl WangLamees AlmuallemJigar DesaiThalia FaraziJinender KumarSaurabh Dahiya
- [48] Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Bahlis, Nizar J.Usmani, Saad ZafarRosinol, LauraKrishnan, Amrita Y.Nooka, Ajay K.Rocafiguera, Albert OriolDelforge, MichelGarfall, Alfred L.Van De Donk, Niels W. C. J.Iguez-Otero, Paula Rodr .Martin, Thomas G.Diels, JorisVan Sanden, SuzyPei, LixiaAmmann, EricKobos, RachelSlavcev, MarySmit, JenniferLondhe, AnilMoreau, Philippe
- [49] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)VALUE IN HEALTH, 2023, 26 (12) : S5 - S6Moreau, P.Usmani, S. Z.van de Donk, N. W. C. J.Garfall, A. L.Delforge, M.Oriol, A.Nooka, A.Rosinol, L.Bahlis, N.Rodriguez Otero, P.Martin, T. G.Diels, J.Van Sanden, S.Pei, L.Ammann, E.Chastain, K.Marshall, A.Slavcev, M.Londhe, A.Krishnan, A.
- [50] ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Hillmen, PeterBrown, Jennifer R.Byrd, John C.Eichhorst, BarbaraLamanna, NicoleO'Brien, Susan MaryQiu, LuguiPaik, Jason C.Hilger, James D.Huang, JaneTam, Constantine S.